trending Market Intelligence /marketintelligence/en/news-insights/trending/v2-kgRrJ8HO3k1ijZ_MFgA2 content esgSubNav
In This List

LBT Innovations laboratory instrument gets US FDA clearance

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Blog

Essential IR Insights Newsletter - Summer July-August 2023

Blog

Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits


LBT Innovations laboratory instrument gets US FDA clearance

Australia's LBT Innovations Ltd. said its APAS Independence instrument received the U.S. Food and Drug Administration's 510(k) clearance.

The APAS Independence instrument with associated urine analysis module allows the automatic reading of culture plates, streamlining the plate triaging stage in the microbiology workflow.

The commercial instrument, classified as a class II medical device, was developed by Clever Culture Systems, LBT Innovations' 50%-owned joint venture unit.

Adelaide, South Australia-based LBT Innovations is engaged in the research and development of technologies for the healthcare and laboratory supply markets in Australia, Switzerland and the U.S.